Home  About us  Contact
 

Metabolic Risk (metabolic + risk)

Distribution by Scientific Domains
Medical Sciences100%

Terms modified by Metabolic Risk

  • metabolic risk factor
    		•

    Selected Abstracts

    The metabolic syndrome and schizophrenia

    ACTA PSYCHIATRICA SCANDINAVICA, Issue 1 2009
    J. M. Meyer
    Objective:, To summarize the accumulated data on metabolic syndrome prevalence in patients with schizophrenia, examine evidence for a biological contribution of the mental illness to metabolic risk and review novel options available for management of prediabetic states. Method:, A Medline search using metabolic syndrome, insulin resistance and insulin sensitivity cross-referenced with schizophrenia was performed on articles published between 1990 and May 2008. Results:, Recent evidence indicates that schizophrenia increases predisposition towards metabolic dysfunction independent of environmental exposure. Both fasting and non-fasting triglycerides have emerged as important indicators of cardiometabolic risk, while metformin, thiazolidinediones and GLP-1 modulators may prove promising tools for managing insulin resistance. Conclusion:, Because of lifestyle, disease and medication effects, schizophrenia patients have significant risk for cardiometabolic disease. Routine monitoring, preferential use of metabolically neutral antipsychotics and lifestyle education are critical to minimizing risk, with a possible role for antidiabetic medications for management of insulin resistant states that do not respond to other treatment strategies. [source]

    The RISCK study: testing the impact of the amount and type of dietary fat and carbohydrate on metabolic risk

    NUTRITION BULLETIN, Issue 2 2007
    S. A. Jebb
    [source]

    Glycaemic control and metabolic risk: getting the extra mile from diabetes control

    PRACTICAL DIABETES INTERNATIONAL (INCORPORATING CARDIABETES), Issue 6 2008
    M Devers MBChB, MRCP Specialist Registrar
    Abstract Cardiometabolic risk is an emerging term which has been used to denote the cluster of risk factors defined by the metabolic syndrome and, in addition, to include the newer risk factors which are now recognised to occur in association with dysglycaemia and abdominal obesity. Interventions for diabetes can have effects on cardiometabolic risk factors beyond lowering of hyperglycaemia, and may be an explanation for the reductions in cardiovascular events that are seen with some but not all antidiabetic drugs. Newer antidiabetic agents and the weight-reducing drug, rimonabant, have demonstrated favourable effects on cardiometabolic risk factors and on glycaemia, and should be further studied in long-term cardiovascular outcomes trials. Copyright © 2008 John Wiley & Sons. [source]

    Unfavourable trends in cardiovascular and metabolic risk in paediatric and adult patients with congenital adrenal hyperplasia?

    CLINICAL ENDOCRINOLOGY, Issue 2 2010
    Christiaan F. Mooij
    Summary Context, As a result of the introduction of treatment with glucocorticoids and mineralocorticoids, now 60 years ago, congenital adrenal hyperplasia has become a lifelong chronic disease. Whether long-term treatment of the disease leads to long-term side effects remains unknown. In this respect, especially cardiovascular risk seems to be important. Evidence synthesis, We reviewed the reported prevalence of conventional cardiovascular risk factors, i.e. obesity, insulin resistance, high blood pressure and dyslipidaemia in patients with congenital adrenal hyperplasia. Overall, the studies suggest a tendency towards an increased body mass index and fat mass, the presence of insulin resistance and hypertension, although data are relatively scarce and obtained in heterogeneous populations. Conclusions, Our findings suggest that adult CAH patients tend to have a cluster of metabolic risk factors, which are consistent with the metabolic syndrome. This notion may have consequences for the care for this group of patients. [source]